Tumor cells with PIK3CA mutations are resistant to drugs targeting epidermal growth factor receptor (EGFR) or erythroblastic leukemia viral oncogene homolog 2 (ERBB2), but may be more sensitive to mTOR and PI3K inhibitors (8). Here, ERBB2 is linked to neoplasm.